Antares Pharma, Inc. stock performance trend indicates that the stock price has rallied 17.65% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 66.67% . Looking at the past 52 week period, the stock price is up at 283.61% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Antares Pharma, Inc. has a positive value of 100 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 71.75.
Antares Pharma, Inc. (NASDAQ:ATRS) has climbed 14.75% in the past week and advanced 8.53% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 14.48% and the outperformance has advanced to 7.29% for the last 4 weeks period.
For this week, the average consensus of the stock is rated as a Strong Buy. Antares Pharma, Inc. (NASDAQ:ATRS) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.02 points or 0.71% at $2.8 with 1,842,961 shares getting traded. Post opening the session at $2.81, the shares hit an intraday low of $2.77 and an intraday high of $2.9 and the price was in this range throughout the day. The company has a market cap of $435 million and the number of outstanding shares has been calculated to be 155,242,370 shares. The 52-week high of Antares Pharma, Inc. (NASDAQ:ATRS) is $2.9 and the 52-week low is $0.67.
Company has reported several Insider transactions to the SEC, on Dec 12, 2016, Fred M Powell (CFO) purchased 100,000 shares at 2.03 per share price.On Dec 5, 2016, Leonard S Jacob (director) sold 20,000 shares at 1.97 per share price.On Mar 23, 2016, Peter J Graham (SVP General Counsel, Secretary) purchased 20,000 shares at 0.77 per share price.
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.